Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

The FDA is expected to authorize the Pfizer vaccine for use in children ages 12-15 next week, a major milestone on the path to getting more Americans vaccinated.

Axios Re:Cap digs into how vaccine trials for children are different, what’s ahead this summer and whether young kids may be eligible for vaccinations before next school year with long-time drug discovery researcher and author of the blog "In The Pipeline," Derek Lowe.

Go deeper

May 4, 2021 - Health

Reports: FDA expected to authorize Pfizer for adolescents by next week

Photo: Pavlo Gonchar/SOPA Images/LightRocket via Getty Images

The Food and Drug Administration is expected to authorized the use of the Pfizer-BioNTech coronavirus vaccine for 12- to 15-year-olds by next week, The New York Times reports.

Why it matters: Opening up vaccine eligibility to young people and children will be crucial as the U.S. works to achieve herd immunity.

May 4, 2021 - Health

Pfizer says COVID vaccine generated $3.5 billion in revenue in Q1

Pfizer CEO Albert Bourla. Photo: Steven Ferdman/Getty Images

Pfizer's COVID-19 vaccine generated $3.5 billion in revenue in the first quarter of 2021, which was nearly a fourth of the company's $14.6 billion income during the period, the pharmaceutical giant reported in an earnings call Tuesday.

Why it matters: The vaccine was the biggest source of revenue for Pfizer — which, unlike some of its competitors — elected to collect the profit from sales of its vaccine, the New York Times notes.

Updated 3 hours ago - World

Death toll mounts as fighting between Israel and Hamas intensifies

Palestinian Muslims exchange wishes for Eid al-Fitr, marking the end of the holy month of Ramadan, near a razed building in the northern Gaza Strip town of Beit Lahia, on May 13. Photo: Majdi Fathi/NurPhoto via Getty Images

At least 109 Palestinians and seven people in Israel have been killed since recent fighting between Israel's military and Hamas began Monday.

The big picture: Israel began massing troops on its border with Gaza on Thursday, launching attacks from the air and ground as Hamas continued to fire rockets into Israel.